Alto Neurosciences is halting work on its schizophrenia prospect after the brain-penetrant drug flunked a phase 2 study. The Bay Area biotech evaluated 10 days of treatment with t ...

Schizophrenia is a severe mental disorder affecting about 1% of the population worldwide, and is notoriously difficult to ...

A newly identified gene mutation may help explain why schizophrenia patients struggle to update their understanding of ...

Currently available antipsychotic drugs can help to ‌control a patient's hallucinations and delusions but they don't improve ...

Axsome Therapeutics Inc. AXSM shares are trading up on Wednesday as the company is expanding its portfolio with the ...

A new study from the Massachusetts Institute of Technology suggests that a specific gene mutation prevents patients with ...

Brexpiprazole is linked to reduced symptoms, improved functioning, and greater response compared with placebo in patients ...

UCSF scientists are in a tight race against time, trying to spot telltale brain signals before a person’s first psychotic ...

Caring for a friend or loved one with schizophrenia can often feel all-consuming. You may find yourself sacrificing work, ...

What if one of the most damaging aspects of schizophrenia isn’t a symptom at all, but the crippling impact of social ...

Some US nursing homes may be falsely diagnosing patients with schizophrenia to justify using powerful antipsychotic drugs to manage them.